Literature DB >> 25128743

Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison?

Nanda Gruben1, Ronit Shiri-Sverdlov2, Debby P Y Koonen3, Marten H Hofker4.   

Abstract

Insulin resistance is one of the key components of the metabolic syndrome and it eventually leads to the development of type 2 diabetes, making it one of the biggest medical problems of modern society. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are tightly associated with insulin resistance. While it is fairly clear that insulin resistance causes hepatic steatosis, it is not known if NAFLD causes insulin resistance. Hepatic inflammation and lipid accumulation are believed to be the main drivers of hepatic insulin resistance in NAFLD. Here we give an overview of the evidence linking hepatic lipid accumulation to the development of insulin resistance, including the accumulation of triacylglycerol and lipid metabolites, such as diacylglycerol and ceramides. In particular, we discuss the role of obesity in this relation by reviewing the current evidence in terms of the reported changes in body weight and/or adipose tissue mass. We further discuss whether the activation or inhibition of inflammatory pathways, Kupffer cells and other immune cells influences the development of insulin resistance. We show that, in contrast to what is commonly believed, neither hepatic steatosis nor hepatic inflammation is sufficient to cause insulin resistance. Many studies show that obesity cannot be ignored as an underlying factor in this relationship and NAFLD is therefore less likely to be one of the main drivers of insulin resistance.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Inflammation; Insulin resistance; Kupffer cell; Lipid; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Year:  2014        PMID: 25128743     DOI: 10.1016/j.bbadis.2014.08.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  45 in total

1.  The MST3/STK24 kinase mediates impaired fasting blood glucose after a high-fat diet.

Authors:  Cristina Iglesias; Ebel Floridia; Miriam Sartages; Begoña Porteiro; María Fraile; Ana Guerrero; Diana Santos; Juan Cuñarro; Sulay Tovar; Rubén Nogueiras; Celia M Pombo; Juan Zalvide
Journal:  Diabetologia       Date:  2017-09-27       Impact factor: 10.122

Review 2.  Pathogenesis of Nonalcoholic Steatohepatitis.

Authors:  Mariana Verdelho Machado; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2016-02-27       Impact factor: 22.682

Review 3.  Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.

Authors:  Thomas Greuter; Harmeet Malhi; Gregory J Gores; Vijay H Shah
Journal:  JCI Insight       Date:  2017-09-07

Review 4.  Developmental origins of nonalcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease.

Authors:  Frank T Spradley; Jillian A Smith; Barbara T Alexander; Christopher D Anderson
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-03-06       Impact factor: 4.310

5.  Associations of Insulin Resistance and Glycemia With Liver Enzymes in Hispanic/Latino Youths: Results From the Hispanic Community Children's Health Study/Study of Latino Youth (SOL Youth).

Authors:  Christina M Parrinello; Bryan J Rudolph; Mariana Lazo; Linda C Gallo; Bharat Thyagarajan; Scott J Cotler; Qibin Qi; Tossaporn Seeherunvong; Denise C Vidot; Howard D Strickler; Robert C Kaplan; Carmen R Isasi
Journal:  J Clin Gastroenterol       Date:  2019-02       Impact factor: 3.062

Review 6.  Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy.

Authors:  Yu Zhang; Xinghui Sun; Basak Icli; Mark W Feinberg
Journal:  Endocr Rev       Date:  2017-04-01       Impact factor: 19.871

7.  A novel role of astrocyte elevated gene-1 (AEG-1) in regulating nonalcoholic steatohepatitis (NASH).

Authors:  Jyoti Srivastava; Chadia L Robertson; Kareem Ebeid; Mikhail Dozmorov; Devaraja Rajasekaran; Rachel Mendoza; Ayesha Siddiq; Maaged A Akiel; Nidhi Jariwala; Xue-Ning Shen; Jolene J Windle; Mark A Subler; Nitai D Mukhopadhyay; Shah Giashuddin; Shobha Ghosh; Zhao Lai; Yidong Chen; Paul B Fisher; Aliasger K Salem; Arun J Sanyal; Devanand Sarkar
Journal:  Hepatology       Date:  2017-06-30       Impact factor: 17.425

8.  Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver.

Authors:  Yueli Tian; Jingting Ma; Wudong Wang; Lingjuan Zhang; Jia Xu; Kai Wang; Dongfu Li
Journal:  Mol Cell Biochem       Date:  2016-09-09       Impact factor: 3.396

Review 9.  The role of the p53 tumor suppressor in metabolism and diabetes.

Authors:  Che-Pei Kung; Maureen E Murphy
Journal:  J Endocrinol       Date:  2016-09-09       Impact factor: 4.286

10.  The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction.

Authors:  Che-Pei Kung; Julia I-Ju Leu; Subhasree Basu; Sakina Khaku; Frederick Anokye-Danso; Qin Liu; Donna L George; Rexford S Ahima; Maureen E Murphy
Journal:  Cell Rep       Date:  2016-03-03       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.